Feeds › Clinical trial updates
Clinical trial updates
Drug and device trials that companies register on ClinicalTrials.gov: newly completed phase 3 studies, changes of status and the dates a study is due to finish.
About this data
- What it is
- ClinicalTrials.gov is the US registry of clinical studies. Drug and device makers register their trials there and update the record as each study moves on. We list the studies that companies sponsor, and match the sponsor to a public company when the name lines up. The page opens on Phase 3 studies marked completed, the late-stage trials that come before a request for approval. Change View to see the changes of status we have noticed, or every recent update.
- Who files it
- The sponsor of the study, in its record on ClinicalTrials.gov. The registry is run by the US National Library of Medicine and does not check what sponsors report.
- How current
- We check the registry every day. Sponsors update records on their own schedule, from the same week to months later, so a change can appear in the registry well after it happened.
- Terms
- ClinicalTrials.govClinicalTrials.gov is the US government's registry of clinical studies, run by the National Library of Medicine. Sponsors register a study before it starts and update the record as it goes. The registry does not check what a sponsor reports.Phase 3The late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.statusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).completedThe sponsor has marked the study as finished. It says nothing about whether the treatment worked: results, if any, are reported separately and often later.status changesOur history of status changes starts the day we first stored each study, so a change made before that is not shown. The date is when we noticed the change, which can be later than when the sponsor made it.primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.company matchWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.
- Worth knowing
- A completed study is not a result: the registry says the study ended, not whether the treatment worked. Status changes start on the day we first stored each study, so earlier changes are not shown. Dates are the sponsor's own, and an estimated date can pass without an update. We match sponsors to companies automatically, with a hand-checked list for the large drugmakers, so a study with no ticker may still belong to a public company. This is information about studies, not a forecast of what they will show or of a stock's price.
- Not to be confused with
- FDA approvals and clearances: what the FDA decided, not what a sponsor reports about a study.
All of this comes from ClinicalTrials.gov, the US registry of clinical studies. We are not affiliated with it.
Source and freshness · Information, not investment advice (disclaimer).
Studies updated per day, last 30 days
All industry-sponsored studies Sponsor matched to a public company
By the day the sponsor last updated the study's record. A study updated twice counts once, on its latest day.
Latest clinical trial updates
Showing: ticker CELU · All recent updates
Studies by the date their record was last updated.
| Updated | Study | SponsorWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private. | PhaseThe late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages. | StatusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time). | Enrolled | Primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update. | Source |
|---|---|---|---|---|---|---|---|
| Jul 7, 2026 | PDA001 for the Treatment of Adults With Moderate-to-Severe Crohn's Disease NCT01155362 · Crohn's Disease Human Placenta-Derived Cells PDA001 Intravenous Infusion, V… | CELU Celularity Incorporated | Phase 2 | Completed | 50 | Feb 2012 | Registry ↗ |
| Jun 26, 2026 | Natural Killer Cell (CYNK-001) Infusions in Adults With COVID-19 NCT04365101 · Coronavirus, Coronavirus Infection CYNK-001 | CELU Celularity Incorporated | Phase 1/2 | Terminated | 7 | Aug 30, 2021 | Registry ↗ |
| Jun 12, 2026 | Efficacy and Safety of Intramuscular PDA-002 in Subjects With Diabetic Foot Ulcer With and Without… NCT02264288 · Peripheral Arterial Disease, Diabetic Foot PDA-002, Placebo | CELU Celularity Incorporated | Phase 2 | Terminated | 159 | Feb 27, 2018 | Registry ↗ |
| Jun 8, 2026 | CYNK-001 IV and IC in Combination With IL2 in Surgical Eligible Recurrent GBM With IDH-1 Wild Type NCT05218408 · Astrocytoma, Grade IV, Glioblastoma CYNK-001 systemic and Intra cavity administration | CELU Celularity Incorporated | Phase 1/2 | Withdrawn | 0 | Oct 23, 2021 | Registry ↗ |
| Jun 4, 2026 | Study of PDA-002 in Subjects With Peripheral Arterial Disease and Diabetic Foot Ulcers NCT01859117 · Peripheral Arterial Disease, Diabetic Foot Ulcer PDA-002 | CELU Celularity Incorporated | Phase 1 | Completed | 15 | Oct 1, 2016 | Registry ↗ |
| Apr 29, 2026 | Hemodynamic Effects of Intramuscular PDA-002 in Subjects Who Have Diabetic Foot Ulcer With Peripher… NCT02460081 · Diabetic Foot, Peripheral Arterial Disease PDA-002, Placebo | CELU Celularity Incorporated | Phase 2 | Withdrawn | 0 | Jan 2016 | Registry ↗ |
| Dec 12, 2024 | CYNK-101 in Combination with Trastuzumab and Pembrolizumab in Patients with Locally Advanced Unrese… NCT05207722 · Metastatic HER2 Positive Gastroesophageal Junction Cancer CYNK-101, Pembrolizumab | CELU Celularity Incorporated | Phase 1/2 | Terminated | 1 | Feb 15, 2024 | Registry ↗ |
| Dec 12, 2024 | Natural Killer Cell (CYNK-001) Infusions in Adults with AML NCT04310592 · Leukemia, Leukemia, Myeloid CYNK-001 | CELU Celularity Incorporated | Phase 1 | Terminated | 27 | Jan 20, 2023 | Registry ↗ |
| Feb 16, 2023 | Natural Killer Cell (CYNK-001) Infusions in Adults With Multiple Myeloma NCT04309084 · Multiple Myeloma, Neoplasm, Plasma Cell CYNK-001 | CELU Celularity Incorporated | Phase 1 | Unknown | 29 | Jan 31, 2023 | Registry ↗ |
| Aug 10, 2022 | Natural Killer Cell (CYNK-001) IV Infusion or IT Administration in Adults With Recurrent GBM NCT04489420 · Astrocytoma, Grade IV, Giant Cell Glioblastoma CYNK001-IV, CYNK001-IT | CELU Celularity Incorporated | Phase 1 | Terminated | 3 | Aug 10, 2021 | Registry ↗ |
| Feb 2, 2022 | A Efficacy and Safety Study of Intramuscular Injection of Human Placenta-Derived Cells (PDA-002) in… NCT02552277 · Diabetic Nephropathies, Peripheral Nervous System Diseases PDA-002, Placebo | CELU Celularity Incorporated | Phase 2 | Completed | 26 | Mar 7, 2017 | Registry ↗ |
| Jul 22, 2020 | A Safety Study of Human Cord Blood Derived, Culture-expanded, Natural Killer Cell (PNK-007) Infusio… NCT02955550 · Multiple Myeloma rhIL-2, PNK-007 | CELU Celularity Incorporated | Phase 1 | Completed | 15 | Jul 10, 2018 | Registry ↗ |
| Jul 22, 2020 | A Safety Study of Human Cord Blood Derived, Culture Expanded Natural Killer Cell (PNK-007) Infusion… NCT02781467 · Leukemia, Myeloid, Acute PNK-007, Cyclophosphamide | CELU Celularity Incorporated | Phase 1 | Terminated | 10 | Dec 7, 2017 | Registry ↗ |
| Jul 22, 2020 | Study of Human Placenta-derived Cells (PDA001) to Evaluate the Safety and Effectiveness for Patient… NCT01261403 · Rheumatoid Arthritis PDA001, Vehicle Controlled Placebo | CELU Celularity Incorporated | Phase 2 | Terminated | 26 | Feb 2012 | Registry ↗ |
| Mar 1, 2018 | A Randomized, Double-Blind, Placebo-Controlled Dose-Escalation Study to Determine the Safety and Ef… NCT01769755 · Crohns Disease PDA001, Vehicle Controlled Placebo | CELU Celularity Incorporated | Phase 1 | Completed | 14 | Nov 2014 | Registry ↗ |
| Mar 1, 2018 | Safety of Intravenous Infusion of Human Placenta-Derived Cells (PDA001) for the Treatment of Adults… NCT01440192 · Stage 2 Pulmonary Sarcoidosis, Stage 3 Pulmonary Sarcoidosis PDA001 (cenplacel-L) | CELU Celularity Incorporated | Phase 1 | Terminated | 4 | Feb 2014 | Registry ↗ |
| Mar 1, 2018 | Study of Human Placenta-derived Cells (PDA001) to Evaluate the Safety and Effectiveness for Patient… NCT01310114 · Stroke, Acute, Middle Cerebral Artery Stroke Human Placenta-Derived Cells PDA001- (cenplacel-L), Placebo | CELU Celularity Incorporated | Phase 2 | Terminated | 44 | Mar 2013 | Registry ↗ |
17 items, most recent first (up to 50). Each row links to the study's page on ClinicalTrials.gov. Updated Nov 15, 2026, 7:30 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · FDA approvals and clearances